New targets and delivery systems for antifungal therapy

Medical Mycology

Volumn 38, Issue , 2000, Pages 335-347

  Walsh, T J ^a   Viviani, M A ^b   Arathoon, E ^c   Chiou, C ^a   Ghannoum, M ^d   Groll, A H ^a   Odds, F C ^e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Instituto Igiene Med Prev   (Italy)

^c Unidad de Biologia Molecular   (Guatemala)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Amphotericin B; Drug delivery; Echinocandins; Triazoles

Indexed keywords

1 (2,4 DICHLOROPHENYL) 1 (4 FLUOROPHENYL) 2 (1,2,4 TRIAZOL 1 YL)ETHANOL; 1 (4 CHLOROPHENOXY) 1 (1 IMIDAZOLYL) 3,3 DIMETHYL 2 BUTANOL; 2 (2,4 DIFLUOROPHENYL) 1 [3 [2 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL]VINYL] 1,2,4 TRIAZOL 1 YL] 3 (1,2,4 TRIAZOL 1 YL) 2 PROPANOL; 2 (2,4 DIFLUOROPHENYL) 3 METHYL 2 (1H 1,2,4 TRIAZOL 1 YL) 4 [4 (TRIFLUOROMETHYL)BENZOYL]MORPHOLINE; 2 (2,4 DIFLUOROPHENYL) 6 HYDROXY 3 METHYL 2 (1H 1,2,4 TRIAZOL 1 YL) 4 [4 (TRIFLUOROMETHYL)BENZOYL]MORPHOLINE; 2 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL] 1,2,4 TRIAZOL 3(2H) ONE; 4 [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 1 PIPERAZINYL]PHENYL] 2,4 DIHYDRO 2 [4 (TRIFLUOROMETHOXY)BENZYL] 1,2,4 TRIAZOL 3 ONE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ASPARTIC PROTEINASE; BETA CYCLODEXTRIN; CASPOFUNGIN; CLOTRIMAZOLE; COCHLEATE LIPID CYLINDER; CYCLODEXTRIN DERIVATIVE; CYTOCHROME P450; DRUG VEHICLE; ECHINOCANDIN B DERIVATIVE; ELECTRAZOLE; ERGOSTEROL; FLUCONAZOLE; IMIDAZOLE; ITRACONAZOLE; KETOCONAZOLE; LIPOSOME; MICAFUNGIN; MICONAZOLE; PHOSPHOLIPASE; POSACONAZOLE; RAVUCONAZOLE; SOLID LIPID NANOPARTICLE; T 8581; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRULENCE FACTOR; VORICONAZOLE;

ASPERGILLUS; CANDIDA; CELL MEMBRANE; CELL WALL; CHEMICAL MODIFICATION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; MAXIMUM TOLERATED DOSE; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NEPHROTOXICITY; NONHUMAN; PHARMACOPHORE; PNEUMOCYSTIS CARINII; STRUCTURE ANALYSIS; VIRULENCE; VISUAL DISORDER;

ANTIFUNGAL AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; FUNGI; HUMANS; MYCOSES; TRIAZOLES;

ASPERGILLUS; CANDIDA; PNEUMOCYSTIS CARINII;

EID: 0034505923     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/mmy.38.s1.335.347     Document Type: Article

References (83)

1. Clinical pharmacology of systemic antifungal agents
2. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization
3. Cyclodextrins-enabling excipients: Their present and future use in pharmaceuticals
4. Cyclodextrins: Their future in drug formulation and delivery
5. Itraconazole in cyclodextrin solution
6. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation
7. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers
8. Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole
9. Cochleate lipid cylinders: Formation by fusion of unilamellar lipid vesicles
10. Are cochleates the new lipid-based carrier for oral drug delivery?
11. Cochleate: A new lipid vehicle for amphotericin B
12. Oral administration of amphotericin B with a new AmB-cochleate formulation: Tissue distribution after single and multiple oral dosing
13. Nanoparticles and microparticles for drug and vaccine delivery
14. Biomedical applications of nanotechnology - Implications for drug targeting and gene therapy
15. Efficacy of NS-718, a novel lipid nanosphere-encapsulated amphotericin B, against Cryptococcus neoformans
16. The efficacy and attenuation of nephrotoxicity of NS-718, a novel lipid nanosphere encapsulated amphotericin B against Cryptococcus neoformans infection
17. In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatus
18. Diblock copolymer nanoparticles for drug delivery
19. Polymeric micelles for drug delivery: Solubilization and haemolytic activity of amphotericin B
20. In vitro dissociation of antifungal efficacy and toxicity for amphotericin B-loaded poly (ethylene oxide)-block-poly (beta benzyl L aspartate) micelles
21. Engineering liposomes for drug delivery: Progress and problems
22. Liposomal drug formulations. Rationale for development and what we can expect for the future
23. Amphotericin B liposomes with prolonged circulation in blood: In vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice
24. Superior efficacy of liposomal amphotericin B with prolonged circulation in blood in the treatment of severe candidiasis in leukopenic mice
25. Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats
26. Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice
27. Antimycotic azole. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones
28. Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes
29. Voriconazole (Pfizer Ltd)
30. Sch-56592 (Schering-Plough)
31. BMS-207147 (Eisai Co Ltd)
32. Compounds active against cell walls of medically important fungi
33. Echinocandins and pneumocandins - A new antifungal class with a novel mode of action
34. In vitro susceptibilities of clinical yeasts isolates to a new echinocandin derivative, LY 303366, and other antifungal agents
35. In vitro activity of two echinocandin derivatives, LY 303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi
36. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species
37. Susceptibility of Candida species isolated from the lower gastrointestinal tracts of high-risk patients to the new semisynthetic echinocandin LY 303366 and other antifungal agents
38. In vitro activity of the echinocandin antifungal LY 303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp
39. Comparison of the in vitro activities of the echinocandin LY 303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans
40. In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant Candida species
41. Anti-Pneumocystis activity of LY 303366 and other echinocandin B analogues
42. In vitro evaluation of LY303366 against Candida species clinical isolates and evaluation of efficacy in a murine model of systemic candidiasis
43. LY303366: Comparison of activity in murine models of Aspergillus fumigatus infection
44. LY303366 activity against systemic aspergillosis and histoplasmosis in murine models
45. LY303366 in a rat mucocutaneous vaginal candidiasis model
46. LY303366 activity against in a murine systemic candidiasis model
47. Antifungal efficacy, safety, and single dose plasma pharmacokinetics of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in persistently neutropenic rabbits
48. Efficacy of LY303366, a semisynthetic echinocandin, against fluconazole-resistant esophageal candidiasis
49. Antifungal efficacy, safety, and single dose plasma pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits
50. Efficacy of LY 303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis
51. Noncompartmental single-dose plasma pharmacokinetics of the novel echinocandin LY303366 in rabbits. A novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits
52. LY 303366 single dose pharmacokinetics and safety in healthy male volunteers
53. Activity of MK-0991 (L-743-872), a new echinocandin, compared with those of LY 303366 and four other antifungal agents tested against blood stream isolates of Candida spp
54. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743-872)
55. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species
56. Pneumocandin L-743-872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro
57. Treatment of murine disseminated candidiasis with L-743872
58. Evaluation of the echinocandin antifungal MK-0991 (L-743-872): Efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis
59. Evaluation of pneumocandin L-743872 in neutropenic mouse models of disseminated candidiasis and aspergillosis against a murine systemic candidiasis model
60. Preclinical efficacy of MK-0991 in pancytopenic mouse models of disseminated candidiasis and aspergillosis against a murine systemic candidiasis model
61. Efficacy of MK-991 (L-743-872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii
62. Treatment of histoplasmosis with MK-0991 (L-743,872)
63. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872)
64. Single and multiple dose pharmacokinetics of the antifungal agent MK-0991 in man
65. A randomized, double blind, multicenter trial of MK-0991 (L-743,872) vs amphotericin B (AmB) in the treatment of Candida esophagitis in adults
66. Efficacy of FK 463, a novel water-soluble echinocandin-like lipopeptide in murine models of disseminated candidiasis
67. Efficacy of FK 463, a novel water-soluble echinocandin-like lipopeptide in murine models of pulmonary aspergillosis
68. Pharmacokinetics of FK 463, a novel water-soluble echinocandin-like lipopeptide in animals
69. Phase I study of FK 463, new antifungal agent, in healthy adult male volunteers
70. Host-pathogen interactions: Redefining the basic concepts of virulence and pathogenicity
71. Fungal virulence genes as targets for antifungal chemotherapy
72. The pH of the host niche controls gene expression in and virulence of Candida albicans
73. Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin
74. Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice
75. Emerging targets for novel antifungal therapeutics
76. Potential role of phospholipases in virulence and fungal pathogenesis
77. Extracellular phospholipases as universal virulence factor in pathogenic fungi
78. Cloning and disruption of caPLB1, a phospholipase B gene involved in the pathogenicity of Candida albicans
79. New systematically active antimycotics from the beta-blocker category
80. Role of aspartic proteases in disseminated Candida albicans infection in mice
81. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients
82. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors